FDA’s Office of Generic Drugs (OGD) reports annually on its accomplishments and organization. The reports include a Director’s Message summarizing the year’s activities, data on improved efficiency and recent progress toward Generic Drug User Fee Program (GDUFA) performance goals and commitments, an overview of new guidances and standards, highlights of the latest FDA efforts to communicate with industry and stakeholders, the year’s significant first generic drug approvals, and GDUFA regulatory science plan priorities for the year.

• 2021 Office of Generic Drugs Annual Report
• 2020 Office of Generic Drugs Annual Report
• 2019 Office of Generic Drugs Annual Report
• 2018 Office of Generic Drugs Annual Report
• 2017 Office of Generic Drugs Annual Report
• 2016 Office of Generic Drugs Annual Report
• 2015 Office of Generic Drugs Annual Report